Company facts
- Headquarters
- Warsaw, Indiana
- Most recent report
- 10-Q, filed Nov 4, 2026
- Incorporated
- Delaware
- Filings on record
- 1,004+ filings
- On EDGAR
- CIK 1136869
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 35
News 8 of 110
Prospectuses and Registrations 8 of 41
- 424B5 Prospectus supplement for an offering Nov 9, 2026
- 424B5 Prospectus supplement for an offering Nov 9, 2026
- FWP Free writing prospectus Nov 5, 2026
- FWP Free writing prospectus Nov 5, 2026
- 424B5 Prospectus supplement for an offering Nov 5, 2026
- 424B5 Prospectus supplement for an offering Nov 5, 2026
- S-8 Registration statement for an employee plan Jun 20, 2025
- S-3ASR Automatic shelf registration Feb 25, 2025
Proxies 8 of 21
- DEFA14A Extra proxy material Apr 1, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 1, 2026
- DEFA14A Extra proxy material Apr 14, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 14, 2025
- PRE 14A Preliminary proxy statement Apr 2, 2025
- DEFA14A Extra proxy material Mar 27, 2024
- DEF 14A Proxy statement for a shareholder vote Mar 27, 2024
- DEFA14A Extra proxy material Mar 30, 2023
Ownership 8 of 772
- 4 Insider reported a trade Oct 5, 2026
- 3 Insider reported their initial holding Oct 5, 2026
- 3 Insider reported their initial holding Oct 5, 2026
- 4 Insider reported a trade Oct 2, 2026
- 4 Insider reported a trade Oct 2, 2026
- 4 Insider reported a trade Oct 2, 2026
- 4 Insider reported a trade Oct 2, 2026
- 4 Insider reported a trade Oct 2, 2026
Other 8 of 25
- SD Conflict minerals disclosure May 27, 2026
- ARS Annual report sent to shareholders Apr 1, 2026
- SD Conflict minerals disclosure May 23, 2025
- ARS Annual report sent to shareholders Apr 14, 2025
- DFAN14A Jan 29, 2025
- DFAN14A Jan 29, 2025
- CERT Exchange certified a listing Nov 22, 2024
- 8-A12B Registration of a security for exchange listing Nov 20, 2024
What to read: Sep 2026 10-Q
SECSift found 2 of 13 sections worth reading, with 0 positive, 14 notable, and 1 negative flags.
Financial Statements (Item 1)
Three Q3 2026 acquisitions ($754.9M total), $585.2M YTD buyback, debt maturity wall, and segment change.Notable- New Manufacturing Network Optimization Plan to exit part of Winterthur facility, ~$60M exit costs expected.
- Three acquisitions closed in Q3 2026 for total consideration of $754.9M, adding $418.2M goodwill.
- Global Foot and Ankle reporting unit's fair value exceeded carrying value by only ~5%, impairment risk.
- Segment reorganization moved Foot & Ankle results and centralized R&D/marketing costs into Americas.
- Litigation charges rose to $40.7M in nine months ended Sep 30, 2026 from $10.4M a year ago.
- Committed to invest up to $300M in a healthcare innovation fund, callable over four years.
- IEEPA tariff refund receivable recognized; $30M reduced cost of goods sold, $47M reduced inventory/PP&E.
Management's Discussion (Item 2)
Full MD&A with segment results, cash flows, debt maturities, and a large customer concentration.Notable- Net earnings dropped to $191.6M in Q3 2026 from $230.9M in Q3 2025, due to non-recurring contingent consideration adjustments.
- Cash from operations rose to $1,367.2M in nine months 2026 from $1,179.7M in 2025, helped by lower restructuring payments.
- Share repurchases of $579.3M in nine months 2026, up from $237.0M in same period 2025; $924.7M remains authorized.
- Debt of $7,504.2M at Q3 2026, with $1,287.7M current including $567.7M notes due Dec 2026 and $600M due Feb 2027.
- New $1.5B share repurchase program authorized Feb 2026, with no expiration date; $924.7M remaining.
- Litigation liabilities estimated at $139.0M as of Q3 2026, expected to be paid over the next few years.
- Contingent consideration payments could range from $0 to $1 billion through 2031, and other commitments up to $465M.
What changed: Sep 2026 vs. Jun 2026
About 6% of ZBH's Sep 2026 10-Q is new information. 16 paragraphs were added, 114 changed, and 23 removed. Below are the most important lines SECSift identified.
New
Changed
- Restructuring expenses fell to $14.4M and $50.5M from $21.4M and $74.9M in the three and nine-month periods.
- Net earnings fell to $191.6M from $230.9M for the three months ended September 30, 2026 vs 2025.
- Net sales rose to $2,062.9M from $2,001.4M for the three months ended September 30, 2026 vs 2025.
- 2026 net sales growth outlook narrowed to 4.4%-4.9% from 3.9%-4.9%, and FX impact estimate cut to 0.25% positive from 0.5%.
- Effective tax rate dropped to 16.2% and 19.8% from 17.2% and 22.6% in the three and nine-month periods.
Everything here comes from Zimmer Biomet Holdings, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Nov 5, 2026, from the 10-Q for Sep 2026.